2014 was a year of growth for AstraZeneca Plc as the company restocked its late-stage portfolio and invested in collaborations that will strengthen its core therapeutic areas of cardiovascular and metabolic medicines, respiratory drugs and oncology. Revenue was up by 3% on a currency adjusted basis. But 2015 is expected to be tougher as generic competition emerges in the US for Nexium, the proton pump inhibitor that was a pillar of the company’s sales for many years.
